

NCT00344318 Processed comparison:

Summary:
CHIA has 17 criteria while your personal folder has 17 criteria
Total found criteria: 12/17
Total not Found: 5/17
Total Extra: 0
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Use of any investigational or non-registered       │ Use of any investigational or non-registered       │
│ product (drug or vaccine) other than the study     │ product (drug or vaccine) other than the study     │
│ vaccine(s) within 30 days preceding the first dose │ vaccine(s) within 30 days preceding the first dose │
│ of study vaccine or planned use during the study   │ of study vaccine or planned use during the study   │
│ period                                             │ period                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic administration (defined as more than 14    │ Chronic administration (defined as more than 14    │
│ days) of immunosuppressants or other immune-       │ days) of immunosuppressants or other immune-       │
│ modifying drugs within six months prior to the     │ modifying drugs within six months prior to the     │
│ first vaccine dose                                 │ first vaccine dose                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Planned administration/ administration of a        │ Planned administration/ administration of a        │
│ vaccine not foreseen by the study protocol during  │ vaccine not foreseen by the study protocol during  │
│ the period starting one month before each dose of  │ the period starting one month before each dose of  │
│ vaccine(s) and ending 7 days after dose 1 and dose │ vaccine(s) and ending 7 days after dose 1 and dose │
│ 2 or 1 month after dose 3                          │ 2 or 1 month after dose 3                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous vaccination against diphtheria tetanus    │ Previous vaccination against diphtheria tetanus    │
│ pertussis polio hepatitis B Haemophilus influenzae │ pertussis polio hepatitis B Haemophilus influenzae │
│ type b and/or S pneumoniae with the exception of   │ type b and/or S pneumoniae with the exception of   │
│ vaccines where the first dose can be given within  │ vaccines where the first dose can be given within  │
│ the first two weeks of life according to the       │ the first two weeks of life according to the       │
│ national recommendations                           │ national recommendations                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of or intercurrent diphtheria tetanus      │ History of or intercurrent diphtheria tetanus      │
│ pertussis hepatitis B polio and Haemophilus        │ pertussis hepatitis B polio and Haemophilus        │
│ influenzae type b diseases                         │ influenzae type b diseases                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of allergic disease or reactions likely to │ History of allergic disease or reactions likely to │
│ be exacerbated by any component of the vaccines    │ be exacerbated by any component of the vaccines    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of seizures (this criterion does not apply │ History of seizures (this criterion does not apply │
│ to subjects who have had a single uncomplicated    │ to subjects who have had a single uncomplicated    │
│ febrile convulsion in the past) or neurological    │ febrile convulsion in the past) or neurological    │
│ disease                                            │ disease                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute disease at the time of enrolment             │ Acute disease at the time of enrolment             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any confirmed or suspected immunosuppressive or    │ Any confirmed or suspected immunosuppressive or    │
│ immunodeficient condition based on medical history │ immunodeficient condition based on medical history │
│ and physical                                       │ and physical                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A family history of congenital or hereditary       │ A family history of congenital or hereditary       │
│ immunodeficiency                                   │ immunodeficiency                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major congenital defects or serious chronic        │ Major congenital defects or serious chronic        │
│ illness                                            │ illness                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Administration of immunoglobulins and/or any blood │ Administration of immunoglobulins and/or any blood │
│ products since birth or planned administration     │ products since birth or planned administration     │
│ during the active phase of the study               │ during the active phase of the study               │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                               │
╞═══════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Male or female between and including 6-12 weeks (42 to 90 days) of age at the time of the first   │
│ vaccination                                                                                       │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects for whom the investigator believes that their parents/guardians can and will comply with │
│ the requirements of the protocol                                                                  │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Written informed consent obtained from the parent or guardian of the subject                      │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Free of obvious health problems as established by medical history and clinical examination before │
│ entering into the study                                                                           │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Born after a gestation period between 36 and 42 weeks                                             │
╘═══════════════════════════════════════════════════════════════════════════════════════════════════╛



We had Nothing Extra